FTC/Industry Showdown Over Orange Book Patent Listings Could Come In 2024

 
• By Brenda Sandburg
  
Generate a summary of this article
Listen to this article
Beta

GlaxoSmithKline, Amneal and Kaleo delist patents on inhalers and autoinjectors in drug-device combination products in response to FTC criticism. But AstraZeneca, Boehringer Ingelheim, and Teva hold firm, teeing up legal battles if the Commission takes enforcement action.

ftc orange book patents
Battles over Orange Book patent listings seem likely as companies reject FTC claims of improper listings. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

The US Federal Trade Commission’s muscling into the arena of Orange Book patent listings could put pressure on the US Food and Drug Administration to finally issue guidance on whether sponsors can list drug delivery devices. It could also lead to litigation if the FTC takes enforcement action against companies that decline to delist patents the agency deems to be improperly listed.

In one of the most surprising actions of 2023, the FTC sent letters to eight drug manufacturers contending they had...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pink Sheet Perspectives

Nancy Tests Tableau for Bridget

This is a short description.

Navigating The EU's Revised Clinical Trial Disclosure Rules

 
• By Vibha Sharma

The European Medicines Agency is preparing to roll out simplified transparency rules for its Clinical Trials Information System in mid-2024. This article looks at what will change and the impact on the thousands of trials that are already in the system.

EU’s Innovative Drug Approval Tally Shows Sharp Decline

 
• By Ian Schofield

The numbers may be down, but Europeans will in future be able to gain access to a number of highly innovative medicines, including several products for hard-to-treat cancers, a gene therapy for severe and moderately severe hemophilia B, and two vaccines against disease caused by respiratory syncytial virus.

As 2024 Begins, US FDA’s Novel Agent Prospects Look A Lot Like 2023

 
• By Bridget Silverman

Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.

More from Pink Sheet

COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’

 
• By Sue Sutter

Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’

Nancy Tests New Podcast Template

 
• By Derrick Gingery

Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.

PinkSheet-R&D-Free: ‘Ranking’ article that includes different Composer content

 
• By Nabil, Olga Zviezdicheva, Reed Miller, Mary Jo Laffler, Ian Schofield, João Andrés-Ruíz de la Fontaine-LeBlanc, Chloë Anastasía-Stojanović del Castillo-Ribeirão, and Nabil

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.